EA201591191A1 - Антитела против ntb-a и связанные с ними композиции и способы - Google Patents

Антитела против ntb-a и связанные с ними композиции и способы

Info

Publication number
EA201591191A1
EA201591191A1 EA201591191A EA201591191A EA201591191A1 EA 201591191 A1 EA201591191 A1 EA 201591191A1 EA 201591191 A EA201591191 A EA 201591191A EA 201591191 A EA201591191 A EA 201591191A EA 201591191 A1 EA201591191 A1 EA 201591191A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ntb
methods
antibodies against
related compositions
provides
Prior art date
Application number
EA201591191A
Other languages
English (en)
Other versions
EA031025B1 (ru
Inventor
Тим Льюис
Чэ-Леунг Ло
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of EA201591191A1 publication Critical patent/EA201591191A1/ru
Publication of EA031025B1 publication Critical patent/EA031025B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Настоящее изобретение предлагает антитела, в том числе конъюгаты антител с лекарственными средствами, способные специфически связываться с NTB-A. Изобретение также предлагает способы применения антител против NTB-A для детекции или модуляции активности (например, ингибирования пролиферации) NTB-A-экспрессирующих клеток, а также для диагностики или лечения заболеваний или расстройств (таких как рак), ассоциированных с NTB-A-экспрессирующими клетками. Кроме того, изобретение предлагает способ лечения множественной миеломы с использованием конъюгата антитела против NTB-A с лекарственным средством, который необязательно включает в себя антитело против NTB-A, раскрытое в данном документе.
EA201591191A 2012-12-21 2013-12-20 Антитела против ntb-a и связанные с ними композиции и способы EA031025B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261745239P 2012-12-21 2012-12-21
PCT/US2013/077264 WO2014100740A1 (en) 2012-12-21 2013-12-20 Anti-ntb-a antibodies and related compositions and methods

Publications (2)

Publication Number Publication Date
EA201591191A1 true EA201591191A1 (ru) 2015-11-30
EA031025B1 EA031025B1 (ru) 2018-11-30

Family

ID=50979291

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591191A EA031025B1 (ru) 2012-12-21 2013-12-20 Антитела против ntb-a и связанные с ними композиции и способы

Country Status (10)

Country Link
US (4) US9708404B2 (ru)
EP (1) EP2934585B1 (ru)
JP (4) JP6449777B2 (ru)
CN (2) CN107880126B (ru)
AU (1) AU2013364043B2 (ru)
CA (1) CA2893977C (ru)
EA (1) EA031025B1 (ru)
HK (1) HK1216850A1 (ru)
IL (2) IL239211B (ru)
WO (1) WO2014100740A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5659014B2 (ja) * 2007-08-02 2015-01-28 ジリード バイオロジクス，インク． 線維症、腫瘍浸潤、血管新生及び転移の治療及び診断のための方法及び組成物
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
BR112017004510A8 (pt) * 2014-09-09 2018-06-26 Univ Texas anticorpos monoclonais isolados; anticorpos monoclonais ou fragmentos de ligação a antígenos do mesmo; composição; moléculas polinucleotídicas isoladas; polipeptídeo recombinante; polipeptídeos; célula hospedeira; método de fabricação de um anticorpo; uso de um agente para o tratamento de câncer em um paciente; usos de anticorpo monoclonal ou fragmento de ligação a antígenos do mesmo para o tratamento de um sujeito que sofre de um câncer; uso de anticorpo monoclonal para o tratamento de um sujeito que sofre de um câncer; composição compreendendo um anticorpo de ligação a agr2; composição compreendendo um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo de ligação a agr2 e um anticorpo de ligação a c4.4a; composição compreendendo um anticorpo; uso de um anticorpo de ligação a agr2; uso de um anticorpo de ligação a c4.4a; uso de um anticorpo; e kit compreendendo um anticorpo
DK3110447T3 (da) * 2014-09-16 2020-06-22 Synermore Biologics Co Ltd Anti-EGFR-antistof og anvendelser heraf
AU2015327064B2 (en) * 2014-09-30 2021-03-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to L1CAM (CD171)
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
IL303690A (en) * 2015-06-30 2023-08-01 Seagen Inc Anti–NTB–A antibodies and related preparations and methods
TWI800341B (zh) 2015-11-03 2023-04-21 美商健生生物科技公司 抗cd38抗體之皮下調配物及其用途
KR20200079293A (ko) 2017-10-31 2020-07-02 얀센 바이오테크 인코포레이티드 고위험 다발성 골수종을 치료하는 방법
EP3752533A4 (en) * 2018-02-13 2021-05-05 Precision Biologics, Inc. TREG CELL TARGETING METHODS AND COMPOSITIONS
US20220372137A1 (en) 2019-07-03 2022-11-24 Oxford Biotherapeutics Ltd Antibodies and methods of use
EP4069374A1 (en) 2019-12-06 2022-10-12 Thoas Fioretos Novel agents and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5515508A (en) 1993-12-17 1996-05-07 Taligent, Inc. Client server system and method of operation including a dynamically configurable protocol stack
AU5752696A (en) * 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO2001053466A1 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Methods and materials relating to semaphorin-like polypeptides and polynucleotides
CA2398546A1 (en) 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to cd84-like polypeptides and polynucleotides
AU2001253362A1 (en) 2000-04-13 2001-10-30 Smith Kline Beecham Corporation Novel compounds
AU2001274888A1 (en) 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6464770B1 (en) 2000-08-08 2002-10-15 Advanced Minerals Corporation Perlite products with controlled particle size distribution
AU2002216610A1 (en) 2000-09-01 2002-04-02 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7795412B2 (en) 2000-09-15 2010-09-14 Genentech, Inc. Nucleic acids encoding PRO6308 polypeptides and related vectors and host cells
EP1223218A1 (en) 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
EP1409655A4 (en) 2001-03-12 2005-04-06 Incyte Genomics Inc SUPERFAMILY PROTEINS OF IMMUNOGLOBULINS
EP1406928B1 (en) 2001-07-19 2010-04-14 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
MXPA04001986A (es) 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
CA2476555A1 (en) 2002-02-14 2003-08-21 Nuvelo, Inc. Methods of therapy and diagnosis
AU2003247806B2 (en) 2002-07-08 2009-11-12 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
JP2006517094A (ja) 2002-10-22 2006-07-20 ヌベロ， インコーポレイテッド 新規核酸およびポリペプチド
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
US20080299042A1 (en) 2004-04-30 2008-12-04 Biogen Idec Ma Inc. Membrane Associated Molecules
EA016357B1 (ru) 2004-07-30 2012-04-30 Ринат Ньюросайенс Корп. Антитела, направленные против бета-амилоидного пептида, и способы их применения
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
CA2614436C (en) 2005-07-07 2016-05-17 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
CN101312748A (zh) * 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
US7847067B2 (en) * 2006-08-28 2010-12-07 ARCA Biopharma Antibodies to NTB-A
US8375932B2 (en) * 2007-10-03 2013-02-19 Germans Boada, S.A. Manual ceramics cutter
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
HUE031533T2 (hu) 2007-10-19 2017-07-28 Seattle Genetics Inc CD19-kötõszerek valamint alkalmazásuk
KR20110050541A (ko) 2008-08-29 2011-05-13 심포젠 에이/에스 항-ｃｄ５ 항체
CN102333859B (zh) * 2008-09-16 2015-04-22 三井化学株式会社 由来自植物的原料生产乳酸的方法及生产乳酸的细菌
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
MX346002B (es) 2009-06-17 2017-03-01 Abbvie Biotherapeutics Inc Anticuerpos anti-vegf y sus usos.
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US8303093B2 (en) * 2009-12-15 2012-11-06 Xerox Corporation Print head having a polymer layer to facilitate assembly of the print head
BR112012017696A2 (pt) 2010-01-18 2017-10-03 Novo Nordisk Healthcare Ag Purificação de fatores de coagulação de sangue
UA108227C2 (xx) * 2010-03-03 2015-04-10 Антигензв'язуючий білок
KR101820987B1 (ko) 2010-04-15 2018-01-22 프로제닉스 파머슈티컬스, 인코포레이티드 클로스트리듐 디피실리 관련 감염 및 질병의 치료를 위한 항체
WO2012047427A2 (en) * 2010-08-31 2012-04-12 The Regents Of The University Of California Antibodies for botulinum neurotoxins
TWI664191B (zh) 2010-11-22 2019-07-01 天賜製藥公司 Ｎｋ細胞調節治療及治療血液惡性疾病之方法
LT2731677T (lt) 2011-07-11 2018-07-10 Glenmark Pharmaceuticals S.A. Antikūnai, kurie prisiriša prie ox40, ir jų panaudojimas
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
IL303690A (en) * 2015-06-30 2023-08-01 Seagen Inc Anti–NTB–A antibodies and related preparations and methods

Also Published As

Publication number Publication date
IL271305B (en) 2021-01-31
CN107880126A (zh) 2018-04-06
CN107880126B (zh) 2021-03-30
IL271305A (en) 2020-01-30
AU2013364043A1 (en) 2015-06-18
WO2014100740A1 (en) 2014-06-26
US9708404B2 (en) 2017-07-18
JP2022066565A (ja) 2022-04-28
US20190375841A1 (en) 2019-12-12
US10435468B2 (en) 2019-10-08
EP2934585A1 (en) 2015-10-28
JP6817674B2 (ja) 2021-01-20
JP2016503067A (ja) 2016-02-01
CN105188749A (zh) 2015-12-23
JP6449777B2 (ja) 2019-01-09
US20150376276A1 (en) 2015-12-31
JP2020055870A (ja) 2020-04-09
EP2934585B1 (en) 2018-06-13
US20230105802A1 (en) 2023-04-06
EP2934585A4 (en) 2016-07-13
IL239211A0 (en) 2015-07-30
JP2019014752A (ja) 2019-01-31
CA2893977A1 (en) 2014-06-26
CN105188749B (zh) 2017-12-19
US20170320944A1 (en) 2017-11-09
IL239211B (en) 2020-08-31
CA2893977C (en) 2024-02-13
AU2013364043B2 (en) 2018-01-04
HK1216850A1 (zh) 2016-12-09
EA031025B1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
CY1122278T1 (el) Αντι il-36r αντισωματα
CY1122490T1 (el) Αντισωματα κατα του ανθρωπινου cd38
CY1119445T1 (el) Αντισωματα εναντι του ανθρωπινου gdf8
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
EA201692042A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
TN2014000120A1 (en) Cd27l antigen binding proteins
EA201201273A1 (ru) Моноклональные антитела к с-мет
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
ZA201707869B (en) Anti-ntb-a antibodies and related compositions and methods
MX2021007663A (es) Molecula de union al antigeno especifico para el tejido objetivo.
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201590171A1 (ru) ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b
EA201390472A1 (ru) Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EA201401204A1 (ru) Антитела к il-23p19
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
BR112013021350A2 (pt) anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
BR112016014731A2 (pt) Anticorpos anti-baff
EA201400447A1 (ru) АНТИТЕЛА К CD1d
EA201390467A1 (ru) Композиции антител и способы применения

Legal Events

Date Code Title Description
TC4A Change in name of a patent proprietor in a eurasian patent